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INTRODUCTION
Many oral controlled drug release systems have been 
developed to improve drug bioavailability and release the 
drug for prolonged period of time.[1] The main objective 
of such a drug delivery system is to control the release 
profile of the drug and also retain the drug in gastric 
environment. Moreover, the drug must be released from 
the delivery system in the absorption window, where the 
drug gets maximum absorption.[2] Most of the drug delivery 
carrier systems such as microspheres and nanoparticles 
have been developed to improve the bioavailability and to 
enhance the pharmacokinetic properties, which can lead to 
improve the patient compliance.[3] Microspheres are ideal 
carriers for delivery of the drug in both oral and parental 
routes of administration.[4] Porous microspheres have been 
developed for not only sustaining the drug release profile 
but have also been used to enhance the extent of drug 
release.[5] Short-term sustained release microparticles have 
been synthesized and evaluated as a drug delivery vehicle.[6] 
Carbamazepine (CBZ), an anti-epileptic drug is used 
in the treatment of epilepsy, trigeminal neuralgia, and 
bipolar disorders. The conventional CBZ tablets yield peak 
plasma concentration varying from 4 to 32 h. Irregular 
and delayed absorption of CBZ is attributed to slow 
dissolution rate.[7] Dissolution enhancement of CBZ can 
result in increase in the rate and extent of absorption and 
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hence bioavailability. Several attempts using water-soluble 
carriers have been made to prepare different formulation 
of CBZ solid dosage forms with improved dissolution 
properties.[8-12] Variation in drug dissolution is also due 
to the availability of various physical forms of CBZ. 
CBZ has at least four different polymorphs (I, II, III, 
and IV) and a dihydrate form. Dihydrate of CBZ has 
one-third solubility compared to its anhydrous form. The 
conversion of CBZ to carbamazepine dihydrate (CBD) in 
the gastrointestinal tract is one of the major rate-limiting 
steps in bioavailability of oral dosage forms.  [13] The burst 
release of CBZ from immediate release (IR) dosage forms 
lead to super-saturation of the drug in GIT and facilitates 
formation of CBD and hence offers poor dissolution 
rate and bioavailability. The best way to reduce the 
super-saturation and re-crystallization of CBZ in stomach 
is formulating it as sustained release dosage forms that 
prevent the burst release, super-saturation, and CBD 
formation. CBZ loaded microspheres were synthesized 
and evaluated for their pharmaceutical applicability in both 
oral and non-oral routes of administration. However, no 
short-term sustained release microspheres were reported 
using lipid as a carrier for CBZ. The present investigation 
is focused on the development of lipid-based porous 
microspheres for short-term sustained release delivery 
of CBZ.
MATERIALS AND METHODS
Materials
Commercial CBZ anhydrate was gifted from Bajaj 
Healthcare Pvt. Ltd., Mumbai. HPMC E5 and Eudragit® 
RLPO was kindly gifted from Colorcon Asia and Degussa 
India, respectively. Compritol 888 ATO was generously 
gifted from Lupin Research Park, India. All other chemicals 
used were of HPLC grade or analytical grade. 
Preparation of microspheres
Porous microspheres were prepared by the emulsion 
solvent diffusion method established by Kawashima[14] 
as follows: 0.2 g of CBZ, Eudragit® RLPO (0.05-0.2 g), 
HPMC E5 (0.1 g), and glyceryl benhate (0.05 - 0.2 g) were 
dispersed in a mixture of dichloromethane (8 ml) and 
ethanol (2 ml) at room temperature. The resulting solution 
was poured into an aqueous solution of polyvinyl alcohol 
(1.0 w/v%, 250 ml) at 308C. The resultant emulsion was 
stirred at 500 rpm employing a homogenizer for 3 h. 
Subsequently, the resulting microspheres were collected 
and dried overnight at 40°C. Composition of optimized 
formulations is listed in Table 1. 
Pharmaceutical characterization
Particle size analysis
Particle size measurement was carried out by the optical 
microscopy method. The prepared microspheres were 
subjected for particle size analysis. Microspheres were 
suspended in liquid paraffin and particle size was measured. 
Encapsulation efficacy
The CBZ content in the microspheres was determined 
by pulverizing the CBZ-loaded microspheres (10 mg) 
followed by immersing them in 500 ml water with agitation 
at room temperature for 10 min. After filtration through 
a 0.45 mm membrane filter (Millipore India, Bengaluru), 
the drug concentration was determined at 287.5 nm using 
the UV-visible spectrophotometric method. All samples 
were analyzed in triplicate, and the encapsulation efficiency 
(EE) was calculated according to the following equation:
%Encapsulationefficacy=
WA
WT
×100
WA - Actual drug content; WT - Theoretical drug content.
Thermal analysis
Differential scanning calorimetric (DSC) analyses of 
the CBZ and microspheres were carried out by using 
a differential scanning calorimeter equipped with 
computer analyzer (Shimadzu TA -60 differential scanning 
calorimeter, Shimadzu Corporation, Kyoto, Japan). Samples 
(of 3-7 mg) were heated in a nitrogen atmosphere on an 
aluminum pan at a heating rate of 108C/min over the 
temperature range of 60-200oC.
Crystalline state evaluation
Powder X-ray diffraction (PXRD) patterns were traced 
employing an X-ray diffractometer (Philips PW 1729, 
Table 1: Composition of carbamazepine porous 
microspheres
Batch Code Composition (mg)
CBZ EUD** COM HPMC
SAM 1 200 50 200 -
SAM 2 200 100 200 -
SAM 3 200 150 200 -
SAM 4 200 200 200 -
SAM 5 200 150 50 -
SAM 6 200 100 100 -
SAM 7 200 50 150 -
SAM 8 200 50 200 100
SAM 9 200 100 200 100
SAM 10 200 150 200 100
SAM 11 200 200 200 100J Young Pharm Vol 2 / No 1  9
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Analytical XRD, Holland) for the samples using Ni filtered 
CuK(a) radiation (intensity ratio(a1/a2): 0.500), a voltage 
of 40 KV, a current of 30 mA, and receiving slit of 
0.2 inches. The samples were analyzed over 2u range of 
5.010-39.990o with scanning step size of 0.020 o (2u) and 
scan step time of 1 s.
Scanning electron microscopy
The surface topography of the microparticles was 
examined using optical microcopy and scanning electron 
microscope (Jeol, JSM-5200, Japan, 15 KV). Samples were 
coated with gold film under vacuum using a sputter coater 
(SPI Sputter™ Coating Unit, SPI Supplies, Division of 
Structure Probe, Inc., PA, USA) and then investigated. 
In vitro dissolution studies
Dissolution studies were carried out in 900 ml of distilled 
water as a dissolution medium at 378C (n 5 3) with a 
six flasks USP type 2 dissolution apparatus (Lab India 
Disso 2000, Lab India Pvt. Ltd, Mumbai, India). Freshly 
prepared distilled water was used as a dissolution medium 
because dissolution profile of CBZ was found to be 
independent of pH.[15] To ensure sink condition, during 
dissolution studies, sample equivalent to 50 mg of CBZ 
was subjected to the test, which is less than 30% of 
saturation solubility of anhydrous of CBZ.[16] Samples 
were taken at appropriate time interval. The volume of 
dissolution medium was kept constant throughout the 
run by replacing the removed samples with an equivalent 
volume of fresh dissolution medium. Samples were 
filtered through 0.44 m filter (Whatman®, Clifton, NJ, 
USA), suitably diluted and analyzed at 287.5 nm by using 
a UV-visible spectrophotometer (Pharma spec 1700, 
Shimadzu Corporation, Kyoto, Japan).
RESULTS AND DISCUSSION
Preparation of microspheres
Microspheres prepared by the emulsion solvent diffusion 
method were found to be spherical in nature. The 
solvent diffusion has created a porous morphology 
of microspheres that could allow entrapping the drug 
molecule by the solvent evaporation method. Moreover, the 
porous nature of the microspheres facilitated large surface 
area that was available for drug release. Glyceryl behenate 
was used as a matrix-forming agent for preparation of 
microspheres. Eudragit RLPO was used as core forming 
polymer because it offers pH independent drug release and 
highly permeable film forming ability,[17] which could allow 
the GI fluid penetration inside the microspheres. During 
the preformulation studies, various operation temperatures 
such as 258C, 308C, 408C, and 508C were tried to get optimal 
spherical nature and porosity. The operation temperature 
of 408C was found to be optimal. Homogenization speed 
was considered as critical parameter in the preparation of 
microspheres. Homogenization speed of 500 rpm was 
found to be optimal for preparation of microspheres. 
The speed of less than 500 rpm caused instability of 
emulsion and led to poor spherical shape. Increasing 
the homogenization speed up to 1500 did not affect the 
microsphere size and morphology. More than 1500 rpm 
leads to very fine microsphere that was very difficult to 
separate during the process. HPMC was used as excipient in 
microsphere formulation, which prevents CBD formation. 
The concentration of HPMC had a significant role in 
the formation of microspheres. No microspheres were 
formed in the concentration of HPMC above 200 mg in 
the formulation. The optimal concentration of 100 mg of 
HPMC was selected for further optimization. The present 
study revealed that the emulsion diffusion method was 
found to be suitable for preparation of glyceryl behenate-
based microspheres that will be utilized to prepare sustained 
release dosage form of BCS class 2 drugs.
Pharmaceutical characterization
Particle size analysis
The results obtained from particle size analysis 
revealed that arithmetic mean diameters of synthesized 
microspheres were in the range of 120.00-182.57 mm 
[Table 2]. The content of eudragit in the microspheres 
had influenced the particle size. High concentration 
of eudragit in formulation reduced the particle size of 
microspheres. Maximum percent frequency (26-34%) 
of the particles in high composition compritol (0.2 g) 
batches of SAM 1-5 was found to be at 200 mm. 21 and 
28% frequency of particles was found with 160 mm 
Table 2: Characterization of carbamazepine loaded 
microspheres
Batch code % EE 1 SD* T50% (h) A.M.D (mm)
SAM 1 31.28 1 1.93 3 182.57
SAM 2 43.40 1 0.53 2 175.35
SAM 3 58.55 1 0.88 2 164.40
SAM 4 79.10 1 1.04 1 196.33
SAM 5 59.16 1 2.12 2 167.27
SAM 6 51.38 1 1.75 3 162.37
SAM 7 47.04 1 0.32 4 170.20
SAM 8 19.14 1 1.60 2 150.79
SAM 9 23.57 1 1.52 1 131.85
SAM 10 39.35 1 1.38 0.5 142.22
SAM 11 51.13 1 0.33 0.5 120.00
*n 5 3; A.M.D: Arithmetic mean diameter10   J Young Pharm Vol 2 / No 1
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in batch SAM7 and SAM8, respectively that pose the 
high concentration of eudragit to compritol ratio. The 
particle size analysis studies revealed that the synthesized 
particles were uniform in size and that can be controlled 
by manipulating the formulation parameters. Particle 
size distribution analysis indicated the non-normal 
distribution of microspheres in size [Figure 1].
Encapsulation efficacy
Entrapment efficacy of drug-loaded microspheres was found 
to be in the range of 19.14-79.10% [Table 2]. Entrapment 
efficacy was dependent on the composition of drug as well as 
eudragit. Low content of eudragit and high drug composition 
of drug in formulation led to reduce the entrapment of drug in 
microsphere formulations. SAM4 yields maximum entrapment 
efficacy of 79.10%, whereas minimum entrapment efficacy 
of 19.04% was observed with SAM8. However, CBZ being a 
low solubility drug with high dose required low concentration 
of polymer and/or excipients in dosage form for better 
formulation development. Further research is required to 
improve the biopharmaceutical properties of CBZ using 
porous microspheres as a carrier.
Thermal analysis
Thermal behaviors of CBZ, polymers, physical mixtures, 
and microspheres were characterized by differential 
thermal calorimetric methods. Figure 2 shows the DSC 
thermogram of drug, polymers, and formulation. CBZ 
showed a first melting endothermic peak at 175.618C 
with the fusion enthalpy of 13.7 J/g followed by a second 
endothermic peak at 191.70°C with the fusion enthalpy of 
105.88 J/g. These two endothermic peaks correspond to 
form III and I of CBZ, respectively.[18] DSC thermogram 
of eudragit revealed that there were no endothermic or 
exothermic peaks, which indicated the amorphous nature 
and stability of the polymer in the operation temperature. 
Glyceryl behenate does not show any characteristic peak in 
the temperature range of 100-2008C. The reported melting 
point of glyceryl behenate is 708C that was observed with 
DSC thermogram of drug-loaded microspheres carried 
out in the temperature range of 60-2008C. The physical 
mixture formulation has shown endothermic peak at 
1918C that indicated the melting of CBZ. CBZ was not 
soluble in melted liquid glyceryl behenate and hence the 
drug was found to be in the suspension form above the 
melting point of glyceryl behenate. Further studies such as 
hot stage microscopy are required to confirm this thermal 
event of physical mixture. There was no endothermic 
peak at 1918C in solid dispersion formulation. The 
absence of endothermic peak at 1918C revealed that the 
drug-presented formulation was found to be of amorphous 
nature. Another possible reason for the absence of 
endothermic peak in solid dispersion formulation could 
be entrapment of drug in the microsphere formulation.
Crystalline state evaluation
The solid states of CBZ, polymers, and microspheres 
of CBZ were studied by XRD [Figure 3]. CBZ was 
detected by low-intensity diffraction peak at 2u values of 
10.105° (d value of 8.746), 13.270 (d value of 6.666) and 
18.710° (d value of 4.738).[19] Eudragit does not show any 
characteristic peak in PXRD thermogram. The PXRD 
pattern of eudragit revealed the amorphous nature of 
the polymer. The PXRD pattern of glyceryl behenate 
had shown that two characteristic peak 14.4708 (d value 
of 6.116) and 21.0708 (d value of 4.213) was comparable 
with compritol PXRD. Moreover, PXRD data revealed 
crystalline nature of the polymer. The reduction in peak 
intensity was observed with microsphere formulation 
stating low crystalline nature of the drug on the surface of 
the micropsheres. PXRD data results confirmed that the 
drug present in microspheres was of either low crystalline 
nature or entrapped in microspheres.
Figure 1: Particle size distribution of carbamazepine-loaded 
microspheresJ Young Pharm Vol 2 / No 1  11
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Scanning electron microscopy
Figure 4 illustrates the scanning electron microscopy of the 
microspheres. The prepared microspheres were spherical 
in nature and the size of the microspheres was not found 
to be uniform. The surface morphology analysis revealed 
porous nature of the microsphere that could be useful 
to increase the surface area and dissolution. CBZ micro-
crystals appeared in the surface of the microspheres that 
may give the initial burst release and the drug entrapped 
in the microspheres provided sustained release dissolution 
profile. The solid state SEM analysis also revealed that 
the prepared microspheres were found to devoid of 
aggregation particles and hence poses negligible surface 
charges, and hence the microspheres were found to be 
physical stability. The high concentration of PVA, which 
was used in the aqueous phase during the preparation of 
microspheres may be one of the suggested reason for 
reducing the particle surface charge and hence provided 
aggregate free microspheres. Prepared microspheres may 
have excellent flow properties and hence there was no 
need of hydrophobic lubricants and glidants for further 
pharmaceutical dosage form development.
In vitro dissolution studies
Figure 5 illustrates the in vitro dissolution profile of 
microspheres. The solubility of CBZ was found to 
be pH independent and hence in vitro dissolution test 
was carried out using distilled water as the dissolution 
medium. CBZ-based microspheres were designed to 
prevent the re-crystallization of the drug by sustaining 
the drug release from the dosage form. Microspheres 
were designed to release the drug in the short-term 
sustained release profile, so that the drug release profile 
was monitored for 6 h. The distal part of GIT has less 
volume of the viscous fluid that may also retard the 
drug release profile of BCS class 2 drugs such as CBZ. 
Figure 2: Differential scanning calorimetric  of (a) Carbamazepine; (b) Eudragit® RLPO; (c) Carbamazepine-loaded microsphere; (d) Physical 
mixture12   J Young Pharm Vol 2 / No 1
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Figure 3: Powder X-ray diffraction of (a) Compritol; (b) Eudragit® RLPO; (c) Carbamazepine; (d) Carbamazepine-loaded microsphere
Figure 4: Surface morphology images of carbamazepine loaded microsphere (a) 350; (b) 330; (c) 3300; (d) 3500
Prepared microspheres had shown the drug release 
profile for 6 h. Prepared microspheres showed T50% 
more than 1 h, which may prevent the re-crystallization 
of CBZ in GIT [Table 2]. The maximum release of 
90.8% was observed with SAM5 formulation, which 
contains low glyceryl behenate and high proportion of J Young Pharm Vol 2 / No 1  13
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for dissolution, which may offer higher extent of drug 
release. However, the effect of polymer on porosity was 
not investigated in this present work. Selected excipients 
were compatible with drug that was characterized by 
DSC studies. CBZ was found to be partly crystalline 
in state and/or entrapped in the microspheres system, 
which was confirmed by PXRD studies. CBZ being a 
high dose drug required large quantity of excipient that 
may be the hurdle for preparation of sizeable dosage 
form. Further investigations are required to reduce the 
amount of polymer in microspheres that can provide 
maximum drug loading and acceptable dosage form. 
More, in vivo behavior of such dosage forms should be 
performed to prove their clinical efficacy.
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Figure 5: In vitro dissolution profiles of carbamazepine-loaded 
microspheres
eudragit. Glyceryl behenate being a lipophilic polymer 
retarded the drug release from the microspheres. High 
permeability of Eudragit RLPO increased the drug 
release in sustained manner. Minimum release of 61.9% 
within 6 h was achieved with high content of glyceryl 
behenate. The drug release profile was dependent on 
the concentration of both the polymers. However, high 
quantity of eudragit had reduced drug release from the 
microspheres. The mechanism for low concentration of 
glyceryl behenate with high content of eudragit batch 
(SAM 5 -SAM 7) is not known. HPMC was used as 
excipient in microspheres (SAM 8-SAM 11) to reduce 
the crystallinty and diffusion layer thickener. HPMC 
increased the extent of drug release up to 20% when 
compared SAM 1 formulation with SAM 8 formulation. 
However, there was no effect of HPMC on the 
formulation containing more than 0.75 g of eudragit. 
In vitro drug dissolution studies revealed that the 
prepared microspheres have optimal drug release profile 
and it can be used for further evaluation. 
CONCLUSION
The present investigation was aimed to prepare short-term 
sustained release microspheres for delivery of CBZ that 
will provide controlled drug release and prevent the 
re-crystallization of drug in GIT. The emulsion solvent 
diffusion method was utilized in the preparation of 
CBZ microspheres. The microspheres prepared by this 
method were found to be of non-uniform in size and 
provided better-controlled release profile of CBZ that 
could prevent the re-crystallization and CBD formation. 
The drug entrapment in microspheres was found to 
be insufficient to prepare pharmaceutically acceptable. 
The drug release from microspheres was found to be 
dependent on the concentration of eudragit as well as 
compritol in microspheres. Prepared microspheres were 
found to be porous in nature that offered high surface area 14   J Young Pharm Vol 2 / No 1
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